http://mobile.journals.lww.com/jnpt/_layouts/15/oaks.journals.mobile/articleviewer.aspx?year=2016&issue=07000&article=00008
Chantraine, Frédéric MD; Schreiber, Céline MSc; Kolanowski, Elisabeth MD; Moissenet, Florent PhD
Journal of Neurologic Physical Therapy
July 2016
Vol. 40 - Issue 3: p 209–215
July 2016
Vol. 40 - Issue 3: p 209–215
Abstract
Background
and Purpose: Abnormal knee hyperextension during the stance phase (genu
recurvatum) is a common gait abnormality in persons with hemiparesis
due to stroke. While ankle-foot orthoses (AFOs) are often used to
prevent genu recurvatum by maintaining ankle dorsiflexion during the
stance phase, AFOs reduce ankle joint mobility. Functional electrical
stimulation (FES) is an alternative to the use of AFO for producing
appropriately timed ankle dorsiflexion and with prolonged timing may
also have value for reducing genu recurvatum.
Case
Description: A 51-year-old man with chronic stroke was the subject of
this case study. The patient had excessive plantarflexion during stance
phase (ie, dynamic equinus foot), with associated genu recurvatum.
Intervention:
Evaluation included clinical examination, instrumented gait analysis,
10-meter walk test, and 6-minute walk test. The patient underwent a
trial of botulinum toxin to the plantarflexor muscles that was not
effective for controlling the genu recurvatum. A subsequent trial with
surface FES to elicit dorsiflexion during gait was effective, and he
subsequently received an implanted FES system.
Outcomes:
Stimulation-induced contraction of the dorsiflexors during terminal
swing phase resulted in improved ankle dorsiflexion at initial contact.
Moreover, extension of stimulation into the loading phase ensured tibial
advancement, which limited knee hyperextension. The patient was
reevaluated 12 months following implantation with continued positive
outcomes.
Discussion: This case study illustrates the
potential value of prolonged timing of dorsiflexor FES to manage genu
recurvatum attributed to a dynamic equinus foot in a stroke survivor.
No comments:
Post a Comment